Monogram's Herceptin theranostic promising
This article was originally published in Clinica
Monogram Biosciences' Herceptin theranostic has shown promise in studies presented at the San Antonio Breast Cancer Symposium, held in Texas, from December 13-16. The trials found that the assay - called HERmark - was not only able to identify patients with the HER2 gene, but also distinguish patients into distinct sub-populations with different clinical outcomes.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.